Gilead Sciences Inc. has chalked up its second failure for its lysyl oxidase-like-2 (LOXL2) inhibitor simtuzumab, virtually killing its prospects, despite continuing trials in other indications.
The big biotech reported Jan. 6 that a Data Safety Monitoring Board (DSMB) recommended that it stop a Phase II clinical trial in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.
The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.
